Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: What do stem cells, ice and ALS have in common?

. You have to be living under a rock – or perhaps spending every minute of your time culturing your cells – to be unaware of the ALS #Icebucketchallenge. Since it began on July 29 on social media, the American ALS Association has raised millions (nearly $42 million at...

Update from the Clinic: July

. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational...

Right Turn: The creative process

I’m starting this post with an image that more or less sums up my life over the past two weeks, which has been rather intensely focused on creativity. This was the second time I traveled to Banff to be part of the Science Communications program at the Banff...

Regenerative Medicine Deal Review: July

. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a...

Stifling Science?

  On June 18, 2014, I walked into the enormous, blue lit plenary hall of the Vancouver Convention Centre excited to hear Canada’s own Janet Rossant give the opening remarks for ISSCR’s Presidential Symposium. I glanced up at the information screens and read, to...

Right Turn: Stem Cell Diabetes Treatment Looking Sweet

. It’s nice to end the week on a happy note. For a company like CCRM that commercializes regenerative medicine products and therapies, the news that ViaCyte, a company based in San Diego, California, has applied to the FDA to start clinical trials for its Type 1...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!